Related Experiment Video

Updated: Jul 10, 2026

Determining Genetic Expression Profiles in C. elegans Using Microarray and Real-time PCR
10:27

Determining Genetic Expression Profiles in C. elegans Using Microarray and Real-time PCR

Published on: July 30, 2011

[Association of cytochrome P450 gene MSP1 polymorphism and risk of preterm]

Ying Jin1, Da-fang Chen, Fan Yang

  • 1Peking University Stem Cell Research Center, Beijing 100083, China.

Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences
|December 18, 2004
PubMed

Insights

The CYP1A1 C/C6235 genotype in both infants and mothers significantly increases preterm delivery risk. This finding highlights the potential role of cytochrome P450 gene variations in preterm birth etiology.

Area of Science:

  • Genetics
  • Obstetrics
  • Pharmacogenomics

Context:

  • Preterm delivery is a leading cause of neonatal morbidity and mortality.
  • Genetic factors, including polymorphisms in drug-metabolizing enzymes, are increasingly recognized as contributors to pregnancy complications.
  • The cytochrome P450 family, particularly CYP1A1, plays a role in metabolizing various endogenous and exogenous compounds.

Purpose:

  • To investigate the association between the CYP1A1 MspI (CYP1A1*2A) polymorphism and the risk of preterm delivery.
  • To determine if infant and maternal genotypes of CYP1A1 MspI influence the likelihood of preterm birth.

Summary:

  • A case-control study of 247 full-term and 249 preterm infant-parent triads in China analyzed CYP1A1 MspI polymorphisms using PCR and restriction enzyme digestion.
  • Results indicated that the CYP1A1 C/C6235 genotype significantly increased the risk of preterm delivery in both infants (RR=1.80) and mothers (RR=1.82).
  • No interaction was observed between maternal and infant genotypes, and control triad variant alleles followed Mendelian transmission.

Impact:

  • The findings suggest that specific CYP1A1 genotypes (C/C6235) may contribute to the etiology of preterm delivery.
  • This highlights the potential importance of pharmacogenetic variability in understanding and potentially predicting preterm birth.
  • Further research into the role of CYP450 gene variability in obstetric outcomes is warranted.
Abstract

More Related Videos

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...